DiaMedica Therapeutics Inc
NASDAQ:DMAC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
DiaMedica Therapeutics Inc
NASDAQ:DMAC
|
US |
|
B
|
Bangkok Expressway and Metro PCL
SET:BEM
|
TH |
DiaMedica Therapeutics Inc
DiaMedica Therapeutics is a clinical-stage drug developer focused on treatments for serious vascular and kidney-related diseases. Its main program is a drug called DM199, a lab-made version of a natural human protein, which the company is testing for conditions such as acute ischemic stroke and preeclampsia. It does not run a drugstore or sell medicines to patients today; it is trying to turn its research into approved treatments that doctors and hospitals could use. The company’s customers, if its drugs succeed, would be hospitals, physicians, and health systems that treat acute and high-risk medical conditions. For now, DiaMedica makes money in the way most early biotech companies do: it raises capital to fund research, clinical trials, and regulatory work, and it may also use partnerships or licensing deals if it finds larger drug makers to help develop or commercialize its programs. What makes its business different is that it is built around a single scientific platform rather than a broad portfolio of products. That means the company’s value depends heavily on whether its lead drug shows clear clinical benefit and can win regulatory approval. In biotech, that kind of focused model can create large upside, but it also carries a high level of scientific and development risk.
DiaMedica Therapeutics is a clinical-stage drug developer focused on treatments for serious vascular and kidney-related diseases. Its main program is a drug called DM199, a lab-made version of a natural human protein, which the company is testing for conditions such as acute ischemic stroke and preeclampsia. It does not run a drugstore or sell medicines to patients today; it is trying to turn its research into approved treatments that doctors and hospitals could use.
The company’s customers, if its drugs succeed, would be hospitals, physicians, and health systems that treat acute and high-risk medical conditions. For now, DiaMedica makes money in the way most early biotech companies do: it raises capital to fund research, clinical trials, and regulatory work, and it may also use partnerships or licensing deals if it finds larger drug makers to help develop or commercialize its programs.
What makes its business different is that it is built around a single scientific platform rather than a broad portfolio of products. That means the company’s value depends heavily on whether its lead drug shows clear clinical benefit and can win regulatory approval. In biotech, that kind of focused model can create large upside, but it also carries a high level of scientific and development risk.
Clinical progress: DiaMedica said it made solid progress across both its preeclampsia and stroke programs and expects multiple clinical milestones through the end of 2027.
Preeclampsia update: The company expects a data update later this quarter from the late-onset preeclampsia extension cohort, and said the next two cohorts should start this summer.
Stroke milestone: ReMEDy2 enrollment has surpassed 70% of the target needed for the interim analysis, which management still expects to complete by the end of 2026.
FDA path: The U.S. early-onset preeclampsia program remains paused on additional nonclinical work, but Canada has already approved the study and the U.K. filing is expected this quarter.
Cash runway: DiaMedica ended the quarter with $51.3 million in cash and investments and said that should fund planned clinical studies and operations through 2027.
